Last edition
News about "Merck"
Moderna and Merck Show Durable Five-Year Benefit for Intismeran-KEYTRUDA in Melanoma
At a median five-year follow-up, intismeran autogene plus KEYTRUDA reduced recurrence or death risk by 49 percent versus KEYTRUDA alone, with further data expected and multiple late-stage trials ongoing across tumour types.
Merck | 22/01/2026 | By News Bureau
Merck Explores USD 28-32 Billion Buyout of Oncology Biotech Revolution Medicines
Merck & Co. is in discussions to acquire U.S.-based oncology biotech Revolution Medicines in a deal that could value the company between USD 28 billion and USD 32 billion, according to people familiar with the matter.
Merck | 11/01/2026 | By Darshana | 164
Merck Completes Acquisition of Cidara Therapeutics to Strengthen Influenza Pipeline
Merck, known as MSD outside the United States and Canada, has announced the successful completion of its cash tender offer, through a subsidiary, to acquire Cidara Therapeutics, Inc.
Merck | 07/01/2026 | By Darshana | 177
Merck Launches ChemiSphere App to Streamline Digital Data Access and Enhance Lab Efficiency
Merck has launched the ChemiSphere app to streamline digital data access and improve lab efficiency by linking physical products with secure digital workflows, enabling quick access to key documentation such as SDS and CoA.
Merck | 17/12/2025 | By News Bureau | 109
FDA Approves Diagnostic Tool for Pembrolizumab Combo in Endometrial Cancer
The US FDA has cleared the OncoMate MSI Dx Analysis System as a companion diagnostic to guide pembrolizumab-based combination therapy in advanced endometrial cancer. The PCR-based assay determines microsatellite instability (MSI) status in tumour tissue, with support from Merck, developer of pembrolizumab and lenvatinib.
Merck | 15/11/2025 | By Dineshwori | 240
Merck Poised to Acquire Cidara Therapeutics in Deal Valued Above USD 3.3 Billion
Merck & Co. is reportedly closing in on the acquisition of Cidara Therapeutics, a biotechnology company focused on long-acting antibody treatments for influenza. The deal is expected to value Cidara above its USD 3.3 billion market capitalisation.
Merck | 14/11/2025 | By Darshana | 108
WINREVAIR from Merck Gains Updated FDA Indication for Pulmonary Arterial Hypertension
Adding WINREVAIR from Merck to background PAH therapy improved exercise capacity and WHO Functional Class (FC), and reduced the risk of clinical worsening events, including hospitalisation for PAH, lung transplantation and death.
Merck | 29/10/2025 | By Dineshwori | 188
Merck KGaA Reports Sustained Efficacy and Safety of OGSIVEO in Phase-III Desmoid Tumour Study
Merck KGaA has released long-term phase-III data showing that OGSIVEO treatment for up to four years continues to deliver durable tumour reductions, improved response rates, sustained symptom relief, and a consistent safety profile in patients with desmoid tumours.
Merck | 27/10/2025 | By Dineshwori | 161
Merck Commits More Than USD 70 Billion to USA Manufacturing and R&D Expansion
A central component of this investment is the construction of a USD 3 billion pharmaceutical manufacturing facility in Elkton, Virginia, which is expected to generate around 500 permanent jobs and several thousand construction roles.
Merck | 21/10/2025 | By Darshana | 239
The data to be presented span Merck’s broad HIV portfolio, including investigational therapies for both treatment and prevention. The presentations will feature new clinical results from Phase 1, 2, and 3 studies evaluating the efficacy, safety, and pharmacokinetics of the company’s next-generation antiviral candidates.
Merck | 13/10/2025 | By Dineshwori | 222
We use our own and third party cookies to produce statistical information and show you personalized advertising by analyzing your browsing, according to our COOKIES POLICY. If you continue visiting our Site, you accept its use.
More information: Privacy Policy